Merck, known as MSD outside the United States and Canada announced that the Food and Drug Administration (FDA) has approved two new HIV-1 medicines: Delstrigo and Pifeltro. The FDA has approved ...

Alector abandoned development of latozinemab as a treatment for frontotemporal dementia (FTD) after it failed a phase 3 trial, and will turn its attention to a midstage Alzheimer's programme. The ...

A US district court has granted an injunction sought by Incyte on the launch of Sun Pharma's recently approved Leqselvi for alopecia areata. In a brief filing with the National Stock Exchange (NSE) of ...

An unsolicited bid by private equity group CVC to take control of Italian pharma company Recordati looks likely to come off, ...

Biogen and Denali have now confirmed that the results show BIIB122 (also known as DNL151) did not slow the progression of ...

Two months after saying it couldn't recommend Genmab's cervical cancer therapy Tivdak for use by the NHS, reimbursement ...

There is only one approved therapy for lung disease non-cystic fibrosis bronchiectasis (NCFB) in the US and Europe – Insmed's ...

Bayer has filed to modify the label for its chronic kidney disease (CKD) Kerendia to include people with type 1 diabetes, ...

Last year, Novo Nordisk accused Singapore-based biotech KBP of concealing clinical data ahead of a $1.3 billion licensing ...

Eli Lilly's triple G agonist retatrutide has achieved weight loss of more than 28% in a new phase 3 trial that keeps it on course for regulatory filings later this year. The readout from the TRIUMPH-1 ...

The phase 2 trial of the new vaccine – known as PF-07872412 or 25vPnC – revealed stronger immune responses to the serotypes ...

The 42-subject pilot study compared three weeks of treatment with Remepy's lead product candidate Hybridopa – which consists ...